title: Chemotherapy and treatment algorithms for follicular lymphoma: a look at all options.
abstract: The outcome of patients with follicular lymphoma has substantially improved in recent years, mainly due to the widespread use of the monoclonal antibody rituximab and partially due to autologous and allogeneic transplantation, and the introduction of new drugs and to the improvement in diagnostic accuracy. The choice of therapy is still based on patient characteristics, extension of disease and clinical prognostic factors. The majority of patients in need of treatment are still treated with cytotoxic agents in combination with rituximab; nevertheless a number of new agents, which are active in this disease, have recently been developed. It has yet to be determined, whether they will partly or completely replace chemotherapy in the near future. This review focuses on the role and the choice of chemotherapy in different clinical situations of follicular lymphoma, in a time when chemotherapy-free treatment becomes more and more of a topic of discussion.
authors.affiliation: a 1 Istituto Oncologico della Svizzera Italiana, Oncology, via Ospedale, Bellinzona, Switzerland.
authors.forename: Sara
authors.initials: S
authors.lastname: Steffanoni
authors.affiliation: b 2 Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland.
authors.forename: Michele
authors.initials: M
authors.lastname: Ghielmini
authors.affiliation: b 2 Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland.
authors.forename: Alden
authors.initials: A
authors.lastname: Moccia
mesh_terms: D000465:Algorithms; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D015195:Drug Design; D006801:Humans; D008224:Lymphoma, Follicular / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D000069283:Rituximab / Q000008:administration & dosage
chemical_list: D000069283:Rituximab
keywords: alkylating agents; anthracycline; bendamustine; chemotherapy; follicular lymphoma; purine analogues; rituximab; targeted therapy